BDBM23911 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-3-oxo-2-[(6-phenoxypyridine-3-)sulfonamido]propyl]benzene-1-carboximidamide::3-amidinophenylalanine deriv., 54

SMILES: [#7]\[#6](-[#7])=[#7]\[#6]-[#6]-[#6]-1-[#6]-[#6]-[#7](-[#6]-[#6]-1)-[#6](=O)-[#6@H](-[#6]-c1cccc(c1)-[#6](-[#7])=[#7])-[#7]S(=O)(=O)c1ccc(-[#8]-c2ccccc2)nc1

InChI Key: InChIKey=OTGQDAVVEHBHSE-VWLOTQADSA-N

Data: 5 KI

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 23911   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Hepatocyte growth factor activator/Serine protease hepsin/Suppressor of tumorigenicity 14 protein (Homo sapiens (Human))	BDBM23911 (3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-y...) Show SMILES [#7]\[#6](-[#7])=[#7]\[#6]-[#6]-[#6]-1-[#6]-[#6]-[#7](-[#6]-[#6]-1)-[#6](=O)-[#6@H](-[#6]-c1cccc(c1)-[#6](-[#7])=[#7])-[#7]S(=O)(=O)c1ccc(-[#8]-c2ccccc2)nc1 |r| Show InChI InChI=1S/C29H36N8O4S/c30-27(31)22-6-4-5-21(17-22)18-25(28(38)37-15-12-20(13-16-37)11-14-34-29(32)33)36-42(39,40)24-9-10-26(35-19-24)41-23-7-2-1-3-8-23/h1-10,17,19-20,25,36H,11-16,18H2,(H3,30,31)(H4,32,33,34)/t25-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	13	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Curacyte Chemistry GmbH					Assay Description The measurements were carried out on a microplate reader. Two concentrations of the substrate and five concentrations of the inhibitor were used. Af...				J Med Chem 49: 4116-26 (2006) Article DOI: 10.1021/jm051272l BindingDB Entry DOI: 10.7270/Q21C1V64
					More data for this Ligand-Target Pair
Thrombin (Bos taurus (Bovine))	BDBM23911 (3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-y...) Show SMILES [#7]\[#6](-[#7])=[#7]\[#6]-[#6]-[#6]-1-[#6]-[#6]-[#7](-[#6]-[#6]-1)-[#6](=O)-[#6@H](-[#6]-c1cccc(c1)-[#6](-[#7])=[#7])-[#7]S(=O)(=O)c1ccc(-[#8]-c2ccccc2)nc1 |r| Show InChI InChI=1S/C29H36N8O4S/c30-27(31)22-6-4-5-21(17-22)18-25(28(38)37-15-12-20(13-16-37)11-14-34-29(32)33)36-42(39,40)24-9-10-26(35-19-24)41-23-7-2-1-3-8-23/h1-10,17,19-20,25,36H,11-16,18H2,(H3,30,31)(H4,32,33,34)/t25-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	99	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Curacyte Chemistry GmbH					Assay Description The measurements were carried out on a microplate reader. Two concentrations of the substrate and five concentrations of the inhibitor were used. Af...				J Med Chem 49: 4116-26 (2006) Article DOI: 10.1021/jm051272l BindingDB Entry DOI: 10.7270/Q21C1V64
					More data for this Ligand-Target Pair
Plasminogen (Homo sapiens (Human))	BDBM23911 (3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-y...) Show SMILES [#7]\[#6](-[#7])=[#7]\[#6]-[#6]-[#6]-1-[#6]-[#6]-[#7](-[#6]-[#6]-1)-[#6](=O)-[#6@H](-[#6]-c1cccc(c1)-[#6](-[#7])=[#7])-[#7]S(=O)(=O)c1ccc(-[#8]-c2ccccc2)nc1 |r| Show InChI InChI=1S/C29H36N8O4S/c30-27(31)22-6-4-5-21(17-22)18-25(28(38)37-15-12-20(13-16-37)11-14-34-29(32)33)36-42(39,40)24-9-10-26(35-19-24)41-23-7-2-1-3-8-23/h1-10,17,19-20,25,36H,11-16,18H2,(H3,30,31)(H4,32,33,34)/t25-/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	1.40E+3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Curacyte Chemistry GmbH					Assay Description The measurements were carried out on a microplate reader. Two concentrations of the substrate and five concentrations of the inhibitor were used. Af...				J Med Chem 49: 4116-26 (2006) Article DOI: 10.1021/jm051272l BindingDB Entry DOI: 10.7270/Q21C1V64
					More data for this Ligand-Target Pair
Factor Xa (fXa) (Bos taurus)	BDBM23911 (3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-y...) Show SMILES [#7]\[#6](-[#7])=[#7]\[#6]-[#6]-[#6]-1-[#6]-[#6]-[#7](-[#6]-[#6]-1)-[#6](=O)-[#6@H](-[#6]-c1cccc(c1)-[#6](-[#7])=[#7])-[#7]S(=O)(=O)c1ccc(-[#8]-c2ccccc2)nc1 |r| Show InChI InChI=1S/C29H36N8O4S/c30-27(31)22-6-4-5-21(17-22)18-25(28(38)37-15-12-20(13-16-37)11-14-34-29(32)33)36-42(39,40)24-9-10-26(35-19-24)41-23-7-2-1-3-8-23/h1-10,17,19-20,25,36H,11-16,18H2,(H3,30,31)(H4,32,33,34)/t25-/m0/s1	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	2.20E+3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Curacyte Chemistry GmbH					Assay Description The measurements were carried out on a microplate reader. Two concentrations of the substrate and five concentrations of the inhibitor were used. Af...				J Med Chem 49: 4116-26 (2006) Article DOI: 10.1021/jm051272l BindingDB Entry DOI: 10.7270/Q21C1V64
					More data for this Ligand-Target Pair
Urokinase-type plasminogen activator (Homo sapiens (Human))	BDBM23911 (3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-y...) Show SMILES [#7]\[#6](-[#7])=[#7]\[#6]-[#6]-[#6]-1-[#6]-[#6]-[#7](-[#6]-[#6]-1)-[#6](=O)-[#6@H](-[#6]-c1cccc(c1)-[#6](-[#7])=[#7])-[#7]S(=O)(=O)c1ccc(-[#8]-c2ccccc2)nc1 |r| Show InChI InChI=1S/C29H36N8O4S/c30-27(31)22-6-4-5-21(17-22)18-25(28(38)37-15-12-20(13-16-37)11-14-34-29(32)33)36-42(39,40)24-9-10-26(35-19-24)41-23-7-2-1-3-8-23/h1-10,17,19-20,25,36H,11-16,18H2,(H3,30,31)(H4,32,33,34)/t25-/m0/s1	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	3.40E+3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Curacyte Chemistry GmbH					Assay Description The measurements were carried out on a microplate reader. Two concentrations of the substrate and five concentrations of the inhibitor were used. Af...				J Med Chem 49: 4116-26 (2006) Article DOI: 10.1021/jm051272l BindingDB Entry DOI: 10.7270/Q21C1V64
					More data for this Ligand-Target Pair